Kolplast Group is positioned to offer solutions that match the world’s best technologies and support the changes in cervical cancer screening
Every two minutes, a woman dies from cervical cancer” (WHO/2024).
This statistic keeps the disease among the ten most common types of cancer worldwide, with more than half a million new cases a year and one of the leading causes of cancer death among women.
The data released in the first quarter of 2024 by the World Health Organization (WHO) underlines the seriousness of the situation and sends a warning to women’s health care networks about the need for action to change this situation.
In Brazil, cervical cancer is the third most common type of cancer and represents the fourth leading cause of death from neoplasms among women.
WHO statistics for countries with low and medium Human Development Indexes (HDI), which include Brazil, predict a significant increase in the incidence of all types of cancer by 2050, with an estimated increase of 1.4 million cases in the country.
These figures highlight the urgent need to improve systems for the prevention, screening and treatment of the disease, with solutions suited to the national scenario.
The Útero é Vida project, linked to the Ministry of Health and started in 2021 in Pernambuco, aims to test a new approach to fighting cervical cancer, based on three fundamental pillars: vaccination against the Human Papillomavirus (HPV), organized screening and qualified treatment.
The pilot project proposes the use of high-performance methods for cancer screening, using tests such as the DNA-HPV test, as well as liquid-based cytology.
The Kolplast Group, which has been developing products for women’s health since its foundation, is positioned to offer solutions that match the best technologies in the world and that support the changes in cervical cancer screening in Brazil with excellence.
The Kolplast Laboratory Line contains CellPreserv Liquid-Based Cytology, a leader in the domestic market.
The CellPreserv preservative solution makes it possible to carry out cytological and molecular tests with a single collection.
The TPK Fênix slide processor is automated and prepares slides with a thin, debris-free cell layer, enabling better diagnostic accuracy.
In addition to cervical-vaginal cytology, the CellPreserv System can be applied to non-gynecological samples.
The method can be used as a single processing for some specimens such as urine and cavitary effusions, or as a complement for more complex diagnostic specimens such as thyroid and salivary glands.
Proper preservation of the material also allows for complementary techniques, such as specific stains or immunocytochemical tests, including processing for cell embeds for complementary diagnoses.
Kolplast products are 100% produced on Brazilian soil, providing efficient logistics and collaborating with the agile service of organizations that are totally suited to local realities and needs.
Cervical cancer screening is a public health challenge.
More than 6% of Brazilian women between the ages of 25 and 64 have never had a Pap smear, according to the National Cancer Institute (INCA).
The barriers that hinder universal access to services for the prevention and treatment of this disease are varied and include systemic health challenges, high costs, logistical problems, as well as cultural, social, religious, geographical, financial and psychological barriers.
To overcome these difficulties, the WHO recommends the adoption of molecular testing for the primary detection of HPV (DNA-HPV testing), reinforcing the role of self-collection as a viable and effective solution.
The method allows the patient to collect the vaginal sample in her own time and in any environment where her intimacy is protected, which reduces the embarrassment and anxiety associated with traditional gynecological exams.
The autonomous approach to screening for Sexually Transmitted Infections (STIs) provided by self-collection is endorsed by the national Útero é Vida project.
The project, in addition to using liquid cytology, is also testing self-collection as a tool to minimize barriers and expand access to early diagnosis, especially for women in remote areas or with difficulties in getting around.
In line with new health technologies and the recommendations of the world’s leading health bodies, the Kolplast Group’s Laboratory Line also presents the Coari Self-Collection Device.
Focused on simplicity, safety and high adherence, the device was developed to ensure effectiveness and ease of use.
Coari includes a collection brush with soft bristles, designed to maximize the material collected without risk of injury.
It also comes with a transport tube that protects the integrity of the sample until it is delivered to the laboratory.
Its cost-benefit ratio is also advantageous and suited to the national reality.
LEARN MORE:
Coari was the first device for self-collection of gynecological samples developed and produced in Brazil in 2016.
It was named after the city of Coari, located on the banks of the Solimões River in the state of Amazonas, where a pioneering study was carried out between 2013 and 2015.
The study evaluated the usefulness of self-collection of cervical-vaginal material for HPV diagnosis.
The aim was to reach women who, in essence, had extreme difficulty in accessing medical care.
The success of the study in Coari demonstrated that self-collection can represent the difference between life and death for many women, especially in remote areas.
100% Brazilian solutions
The Kolplast Group is a Brazilian company that for more than three decades has been dedicated to the development of healthcare solutions.
The company continually invests in research and the development of new technologies, ensuring that its solutions are always one step ahead of the emerging needs of the healthcare system.
This commitment is reflected in the creation of innovative products that promote the prevention and early diagnosis of diseases.
With a robust infrastructure and an ongoing commitment to innovation, the company is able to supply the public health system and private organizations with the best and most modern technologies needed for the prevention and early diagnosis of cervical cancer and other diseases.
And by producing locally, Kolplast is able to reduce costs and improve logistics, facilitating access to its innovations throughout the country.
And is your organization prepared to meet the new demands generated by the World Health Organization’s recommendations?